[go: up one dir, main page]

AR066820A1 - Compuestos de tiadiazolidin-3 ona - Google Patents

Compuestos de tiadiazolidin-3 ona

Info

Publication number
AR066820A1
AR066820A1 ARP080102325A ARP080102325A AR066820A1 AR 066820 A1 AR066820 A1 AR 066820A1 AR P080102325 A ARP080102325 A AR P080102325A AR P080102325 A ARP080102325 A AR P080102325A AR 066820 A1 AR066820 A1 AR 066820A1
Authority
AR
Argentina
Prior art keywords
compounds
thiadiazolidin
naphthalen
dioxo
hydroxy
Prior art date
Application number
ARP080102325A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39720401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR066820(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR066820A1 publication Critical patent/AR066820A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos que son inhibidores de las fosfatasas de proteína tirosina (PTPasas), y por lo tanto, que se pueden emplear para el tratamiento de las condiciones mediadas por la actividad de PTPasa. Los compuestos de la presente también se pueden emplear como inhibidores de otras enzimas caracterizadas por una region de enlace de fosfotirosina, tal como el dominio SH2. De acuerdo con lo anterior, los compuestos de la presente se pueden emplear para la prevencion y/o el tratamiento de resistencia a la insulina asociada con obesidad, intolerancia a la glucosa, diabetes mellitus, hipertension, y enfermedades isquémicas de los vasos sanguíneos grandes y pequenos, condiciones que acompanan a la diabetes tipo 2, incluyendo hiperlipidemia, hipertrigliceridemia, ateroesclerosis, restenosis vascular, síndrome de intestino irritable, pancreatitis, tumores de células adiposas, y carcinomas, tales como liposarcoma, dislipidemia, y otros trastornos en donde se indique la resistencia a la insulina. En adicion, los compuestos de la presente se pueden emplear para tratar y/o prevenir cáncer, osteoporosis, enfermedades neurodegenerativas e infecciosas, y enfermedades que involucren inflamacion y el sistema inmune. Composicion farmacéutica en base al compuesto y uso del compuesto para preparar medicamentos. Reivindicacion 1: Un compuesto, el cual se selecciona a partir del grupo que consiste en: 5-(3-hidroxi-7-metoxi-naftalen-2-il)-1,1-dioxo-[1,2,5]-tiadiazolidin-3-ona; 5-(3-hidroxi-7-propoxi-naftalen-2-il)-1,1-dioxo-[1,2,5]-tiadiazolidin-3-ona; 5-(3-hidroxi-naftalen-2-il)-1,1-dioxo-[1,2,5]-tiadiazolidin-3-ona; y 5-(3-hidroxi-7-metil-naftalen-2-il)-1,1-dioxo-1,2,5-tiadiazolidin-3-ona; o una sal farmacéuticamente aceptable de los mismos.
ARP080102325A 2007-06-04 2008-06-02 Compuestos de tiadiazolidin-3 ona AR066820A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94176807P 2007-06-04 2007-06-04

Publications (1)

Publication Number Publication Date
AR066820A1 true AR066820A1 (es) 2009-09-16

Family

ID=39720401

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102325A AR066820A1 (es) 2007-06-04 2008-06-02 Compuestos de tiadiazolidin-3 ona

Country Status (9)

Country Link
US (1) US20100197744A1 (es)
EP (1) EP2155704A1 (es)
JP (1) JP2010529075A (es)
CN (1) CN101687828A (es)
AR (1) AR066820A1 (es)
CL (1) CL2008001612A1 (es)
PE (1) PE20090762A1 (es)
TW (1) TW200911769A (es)
WO (1) WO2008148744A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101321743A (zh) * 2005-12-08 2008-12-10 诺瓦提斯公司 作为ptp-酶抑制剂的1,1,3-三氧代-1,2,5-噻二唑烷和它们的用途
KR20080074970A (ko) * 2005-12-08 2008-08-13 노파르티스 아게 단백질 티로신 포스파타제 (ｐｔｐａｓｅ)에 의해 매개되는질병의 치료에 유용한 1,2,5-티아졸리딘 유도체
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN105287534A (zh) * 2015-11-11 2016-02-03 朱忠良 一种抗糖尿病的口服药物组合物
CN105520943A (zh) * 2015-11-11 2016-04-27 朱忠良 一种抗糖尿病的口服药物组合物
CN105213381A (zh) * 2015-11-11 2016-01-06 朱忠良 一种抗糖尿病的口服药物组合物
CN105287535A (zh) * 2015-11-11 2016-02-03 朱忠良 一种抗糖尿病的口服药物组合物
CN105232544A (zh) * 2015-11-11 2016-01-13 朱忠良 一种抗糖尿病的口服药物组合物
CN105434433A (zh) * 2015-11-11 2016-03-30 朱忠良 一种抗糖尿病的口服药物组合物
CN105213379A (zh) * 2015-11-11 2016-01-06 朱忠良 一种抗糖尿病的口服药物组合物
CN105250276A (zh) * 2015-11-11 2016-01-20 朱忠良 一种抗糖尿病的口服药物组合物
CN105193801A (zh) * 2015-11-11 2015-12-30 朱忠良 一种抗糖尿病的口服药物组合物
CN105213385A (zh) * 2015-11-11 2016-01-06 朱忠良 一种抗糖尿病的口服药物组合物
CN105193796A (zh) * 2015-11-11 2015-12-30 朱忠良 一种抗糖尿病的口服药物组合物
CN105232546A (zh) * 2015-11-11 2016-01-13 朱忠良 一种抗糖尿病的口服药物组合物
CN105213383A (zh) * 2015-11-11 2016-01-06 朱忠良 一种抗糖尿病的口服药物组合物
CN105232547A (zh) * 2015-11-11 2016-01-13 朱忠良 一种抗糖尿病的口服药物组合物
CN105434434A (zh) * 2015-11-11 2016-03-30 朱忠良 一种抗糖尿病的口服药物组合物
CN105476990A (zh) * 2015-11-11 2016-04-13 朱忠良 一种抗糖尿病的口服药物组合物
CN105213382A (zh) * 2015-11-11 2016-01-06 朱忠良 一种抗糖尿病的口服药物组合物
CN105213384A (zh) * 2015-11-11 2016-01-06 朱忠良 一种抗糖尿病的口服药物组合物
CN105287533A (zh) * 2015-11-11 2016-02-03 朱忠良 一种抗糖尿病的口服药物组合物
CN105213387A (zh) * 2015-11-11 2016-01-06 朱忠良 一种抗糖尿病的口服药物组合物
CN105213380A (zh) * 2015-11-11 2016-01-06 朱忠良 一种抗糖尿病的口服药物组合物
CN105193800A (zh) * 2015-11-11 2015-12-30 朱忠良 一种抗糖尿病的口服药物组合物
CN105193821A (zh) * 2015-11-11 2015-12-30 朱忠良 一种抗糖尿病的口服药物组合物
CN105193797A (zh) * 2015-11-11 2015-12-30 朱忠良 一种抗糖尿病的口服药物组合物
CN105213386A (zh) * 2015-11-11 2016-01-06 朱忠良 一种抗糖尿病的口服药物组合物
CN105232543A (zh) * 2015-11-11 2016-01-13 朱忠良 一种抗糖尿病的口服药物组合物
CN105232545A (zh) * 2015-11-11 2016-01-13 朱忠良 一种抗糖尿病的口服药物组合物
CN105412095A (zh) * 2015-11-11 2016-03-23 朱忠良 一种抗糖尿病的口服药物组合物
CN105287531A (zh) * 2015-11-11 2016-02-03 朱忠良 一种抗糖尿病的口服药物组合物
CN105287532A (zh) * 2015-11-11 2016-02-03 朱忠良 一种抗糖尿病的口服药物组合物
CN105250277A (zh) * 2015-11-11 2016-01-20 朱忠良 一种抗糖尿病的口服药物组合物
CN105232552A (zh) * 2015-11-11 2016-01-13 朱忠良 一种抗糖尿病的口服药物组合物
ES2989988T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros heterorocíclicos para la degradación de proteínas diana
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
WO2018237026A1 (en) 2017-06-20 2018-12-27 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN BREAKDOWN
TW202519515A (zh) * 2019-03-14 2025-05-16 美商嘉來克生命科學有限責任公司 蛋白酪胺酸磷酸酶抑制劑及其使用方法
CN116194453A (zh) * 2019-12-20 2023-05-30 卡里科生命科学有限责任公司 蛋白质酪氨酸磷酸酶降解剂及其使用方法
WO2024243441A1 (en) 2023-05-24 2024-11-28 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2341049A1 (en) * 2002-04-03 2011-07-06 Novartis AG 5-substituted 1,1-dioxo-[1,2,5]thiazolidine-3-one derivatives as PTPASE 1B inhibitors
GB0225986D0 (en) * 2002-11-07 2002-12-11 Astrazeneca Ab Chemical compounds
GB0227813D0 (en) * 2002-11-29 2003-01-08 Astrazeneca Ab Chemical compounds
UA94724C2 (en) * 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents

Also Published As

Publication number Publication date
PE20090762A1 (es) 2009-07-09
CL2008001612A1 (es) 2009-05-15
WO2008148744A1 (en) 2008-12-11
EP2155704A1 (en) 2010-02-24
TW200911769A (en) 2009-03-16
US20100197744A1 (en) 2010-08-05
CN101687828A (zh) 2010-03-31
JP2010529075A (ja) 2010-08-26

Similar Documents

Publication Publication Date Title
AR066820A1 (es) Compuestos de tiadiazolidin-3 ona
ECSP088509A (es) Derivados de 1,2,5-tiazolidinadiona sustituidos por 1-orto-fluoro-fenilo como inhibidores de ptp-asa
ECSP088506A (es) Derivados de tiadiazol como agentes antidiabeticos
Demuro et al. GSK-3β, FYN, and DYRK1A: master regulators in neurodegenerative pathways
Rehman et al. Taxifolin prevents postprandial hyperglycemia by regulating the activity of α‐amylase: Evidence from an in vivo and in silico studies
Lu et al. Gastroprotective effects of Kangfuxin against water-immersion and restraint stress-induced gastric ulcer in rats: roles of antioxidation, anti-inflammation, and pro-survival
Valerio et al. Glycogen synthase kinase‐3 inhibition reduces ischemic cerebral damage, restores impaired mitochondrial biogenesis and prevents ROS production
Sodhi et al. Fructose mediated non-alcoholic fatty liver is attenuated by HO-1-SIRT1 module in murine hepatocytes and mice fed a high fructose diet
BR112021020335A2 (pt) Agonistas glp-1r e usos dos mesmos
TNSN08247A1 (en) 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
UA103272C2 (uk) 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
BR112015003109A2 (pt) Composto, composição, uso de um composto, e, métodos para tratar ou prevenir um distúrbio, condição ou doença e para tratar diabetes mellitus tipo 2.
WO2007115058A3 (en) Thiadiazolidinone inhibitors of ptpase
EA201100119A1 (ru) Химические соединения 251
BR112012014899A2 (pt) composto, composição farmacêutica, método para tratar ou prevenir uma infecção por vírus de hepatite c em um sujeito, método para tratar , prevenir ou melhorar um ou mais sintomas de uma doença hepática ou distúrbio associado a uma infecção por vírus de hepatite c em um sujeito, método para inibir a replicação de um vírus em um hospedeiro, método para inibir a replicação de um vírus
Wang et al. Comparison of hepatotoxicity and mechanisms induced by triclosan (TCS) and methyl-triclosan (MTCS) in human liver hepatocellular HepG2 cells
EA201270666A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
WO2009132238A3 (en) Ido inhibitors
BR122021002201A8 (pt) Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença
EA201300522A1 (ru) Фармацевтические комбинации для лечения метаболических нарушений
BR112014012056A8 (pt) compostos farmacêuticos
NO20044745L (no) 5-substituerte 1,1-diokso-1,2,5-tiazolidin-3-on-derivater som PTPASE 1B inhibitorer
Huang et al. Design, synthesis, and bioevaluation of paeonol derivatives as potential anti-HBV agents
EA200971106A1 (ru) Соединения с семичленным кольцом и их фармацевтические применения для предупреждения и лечения диабета и метаболического синдрома
Zhao et al. Role of the ACE2/Ang-(1-7)/Mas axis in glucose metabolism

Legal Events

Date Code Title Description
FB Suspension of granting procedure